What Reddit Users Say About Their Weight Loss Experience on Wegovy
Analysis of 660 Reddit posts reveals real-world patient narratives about semaglutide 2.4 mg for weight loss, including benefits and challenges.
Quick Facts
What This Study Found
Qualitative analysis of 660 Reddit posts provides rich patient narratives about real-world semaglutide 2.4 mg experiences during a period of high demand and shortages.
Key Numbers
1,000 posts screened from r/WegovyWeightLoss (Oct 2022-Oct 2023). 660 included. 7 themes: efficacy (29.4%), psychosocial impact (22.8%), side effects, access, lifestyle, comparisons, stigma.
How They Did This
Retrospective qualitative analysis of 660 Reddit posts from r/WegovyWeightLoss using collaborative codebook development and qualitative coding.
Why This Research Matters
Clinical trials capture efficacy and side effects, but patient forums reveal the full lived experience — access struggles, emotional journey, and real-world challenges.
The Bigger Picture
Social media analysis captures patient experiences that traditional research misses, informing more patient-centered care and policy discussions around anti-obesity drugs.
What This Study Doesn't Tell Us
Reddit users may not represent all semaglutide patients — skews younger and more tech-savvy. Self-reported data without verification.
Questions This Raises
- ?How do Reddit experiences compare to clinical trial outcomes?
- ?Do supply shortages affect treatment adherence and outcomes?
Trust & Context
- Key Stat:
- 660 posts Reddit posts analyzed from r/WegovyWeightLoss capturing unfiltered patient narratives
- Evidence Grade:
- Qualitative social media analysis — captures authentic patient voice but cannot establish efficacy or generalize to all patients.
- Study Age:
- Published in 2025, covering a critical period of Wegovy adoption and supply challenges.
- Original Title:
- A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.
- Published In:
- Obesity science & practice, 11(4), e70085 (2025)
- Authors:
- Plenn, Eion, Amin, Dylan, Henry, Jonathan, Leavitt, Gabrielle, Walker, Jason, Soleymani, Taraneh
- Database ID:
- RPEP-13067
Evidence Hierarchy
Uses interviews or focus groups to understand experiences in depth.
What do these levels mean? →Frequently Asked Questions
What do real patients say about Wegovy?
Reddit posts reveal a mix of weight loss success stories, side effect experiences, access and shortage frustrations, and emotional narratives about the weight loss journey.
Is Reddit a reliable source for drug information?
While not medically verified, Reddit captures authentic patient perspectives that complement clinical trial data. Always verify with your healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13067APA
Plenn, Eion; Amin, Dylan; Henry, Jonathan; Leavitt, Gabrielle; Walker, Jason; Soleymani, Taraneh. (2025). A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.. Obesity science & practice, 11(4), e70085. https://doi.org/10.1002/osp4.70085
MLA
Plenn, Eion, et al. "A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.." Obesity science & practice, 2025. https://doi.org/10.1002/osp4.70085
RethinkPeptides
RethinkPeptides Research Database. "A Qualitative Analysis of Patient Experiences Using Semaglut..." RPEP-13067. Retrieved from https://rethinkpeptides.com/research/plenn-2025-a-qualitative-analysis-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.